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Background: Activating point mutation of the RAS gene has been generally accepted as an 
  oncogenic event in a variety of malignancies. It represents one of the most common genetic 
alterations in acute myeloid leukemia (AML). However, little is known about its clinical 
  relevance in the treatment outcome for this leukemia.
Objective: This study aimed to clarify the biologic and prognostic impact of K-RAS mutations 
in relation to the dose of cytarabine (ara-C) used in postinduction consolidation chemotherapy 
in adult AML patients.
Patients and methods: The study comprised of 71 de novo AML patients with male/
female ratio 1.4:1; their ages ranged from 21–59 years with a median of 37 years. They 
were subjected to full clinical evaluation, routine laboratory investigations, cytogenetic 
studies by G-banding (Giemsa staining), and K-RAS mutation detection using real-time 
polymerase chain reaction. The patients were randomized into two groups according to 
the ara-C dose used in consolidation treatment, the high the dose ara-C (HDAC) group 
receiving 400 mg ara-C and-low-dose ara-C (LDAC) group receiving 100 mg ara-C; they 
were followed over a period of five years.
Results: Mutations in the K-RAS gene (mutRAS) were detected in 23 patients (32%) with the 
remaining 48 patients (68%) having wild-type RAS (wtRAS). The percent of blast cells was 
significantly lower in mutRAS compared to wtRAS patients (P  0.001) while M4 subtype 
of AML and Inv(16) frequencies were significantly higher in mutRAS compared to wtRAS 
patients (P = 0.015) and (P = 0.003), respectively. The patients were followed up for a median 
of 43 months (range 11–57 months). There was no significant difference in overall survival 
(OS) between mutRAS and wtRAS (P = 0.326). Within the mutRAS patients treated with 
HDAC, cumulative OS was significantly higher than those treated with LDAC (P = 0.001). 
This was not the case in the wtRAS group (P = 0.285). There was no significant difference 
in disease-free survival (DFS) between mutRAS and wtRAS groups (P = 0.923). mutRAS 
patients treated with HDAC had a statistically higher cumulative DFS than mutRAS patients 
treated with LDAC (P = 0.001). Patients with wtRAS also benefited from HDAC, but to a 
lesser extent. Among patients with wtRAS, those treated with HDAC showed higher cumula-
tive and median DFS than patients treated with LDAC (P = 0.031). 
Conclusion: It was concluded that adult AML patients carrying mutations in the K-RAS 
gene benefit from higher ara-C doses more than wtRAS patients, so pretreatment mutation 
detection could be an important predictor for treatment strategy and survival of adult AML 
patients. These findings counter the prevailing bias that oncogene mutations lead to more 
aggressive behavior in human malignancies.
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Introduction
Activating point mutations of RAS genes have been gener-
ally accepted as oncogenic events in the tumorigenesis of a 
variety of malignancies. The mechanisms by which mutant 
RAS (mutRAS) is transforming affected cells have been 
extensively studied. In general, RAS mutations lead to a 
resistance of the RAS proteins to signaling provided by 
guanosine triphosphatase (GTPase)-activating proteins thus 
remaining locked in the active GTP-bound state.1,2 This con-
stitutive activity is furthermore translated via a cascade of key 
signaling events that contribute to the regulation of prolifera-
tion, apoptosis, and differentiation. One example for such a 
signaling cascade is RAS-GTP recruitment of RAF proteins 
to the plasma membrane which leads to activating phospho-
rylation of mitogen-activated protein kinase (MAPK) and 
consequently extracellular signal-regulated kinases (ERK). 
ERK activity has been linked to proliferative stimulation and 
activation of antiapoptotic pathways.3,4
In acute myelogenous leukemia (AML), activating point 
mutations could be shown to affect almost exclusively 
N-RAS and K-RAS at codons 12, 13, and 61. This altera-
tion was detected with varying frequencies (25%–40%) and 
represents one of the most common genetic alterations 
detected in AML.5
Given the potential effect of activating point mutations 
on cellular physiology, one might expect in AML patients 
an association between RAS mutations and an aggressive 
course of the disease. However, under certain conditions, 
RAS activity may even give rise to increased senescence 
and proapoptotic signaling.6,7 Recently, some studies showed 
that there may be interactions between genetic alterations 
and therapeutic modalities. For example, RAS mutations 
harbor poor prognosis in lung cancer without adjuvant che-
motherapy, whereas they are associated with better outcome 
after chemotherapy, which may be caused by a differential 
sensitivity of RAS mutated cells towards cytarabine- (ara-C) 
containing chemotherapy.8,9 Other studies revealed conflict-
ing data and did not show an independent effect of RAS 
mutations on therapy outcome.10,11 Some studies have ana-
lyzed the association of RAS mutation with specific French–
American–British (FAB) subtypes, karyotypes, or blast cell 
tumor load in AML, but the results were conflicting.
This study aimed to clarify the biologic and prognostic 
impact of K-RAS mutations in relation to high- and low-dose 
ara-C used in postinduction consolidation therapy of de novo 
adult AML patients.
Material and methods
Patients
Eighty-nine consecutive patients with de novo AML attend-
ing the Hematology and Oncology Unit, Zagazig University 
Hospital, Egypt were enrolled in this study cohort for the 
biologic and prognostic impact of RAS mutations over a 
period of five years. The age requirement for eligibility was 
greater than 18 years with an upper limit of 60 years. Patients 
having acute promyelocytic leukemia were not enrolled in 
the study. Only patients who achieved a complete remission 
(CR) after one or two courses of induction chemotherapy 
were eligible for inclusion in this analysis of postremission 
therapy. Patients with a prior history of myelodysplasia, other 
antecedent hematologic malignancies, prior nonsteroidal 
cytotoxic   chemotherapy or radiation therapy, pre-existing 
liver disease, or uncontrolled infection were not included 
in the study.   Written informed consent was obtained from 
all patients.
Treatments
Patients received induction chemotherapy of daunorubicin 
45 mg/m2/day intravenously for three days and cytarabine 
200 mg/m2/day as a continuous infusion for seven days. 
Those who attained a CR after one or two courses of induc-
tion therapy (n = 74) were randomly assigned to one of two 
postinduction arms that differed in dose-intensity of ara-C. 
These arms included four cycles of (a) high-dose in ara-C 
(HDAC) at 400 mg/m2 as a continuous infusion for five days 
or (b) low-dose ara-C (LDAC) at 100 mg/m2 as a continu-
ous infusion for five days. In each case, this was followed 
by maintenance treatment consisting of four monthly treat-
ments with ara-C (100 mg/m2 every 12 hours) for five days 
by subcutaneous injection and daunorubicin 45 mg/m2 on 
the first treatment day. Thereafter, patients were followed 
up with bone marrow (BM) examination every three months 
for one year, every six months for two years, and then every 
year for two additional years.
Methods
All patients were subjected to the following: full clinical 
assessment including history taking, clinical examination and 
abdominal ultra sonography, liver and kidney function tests, 
complete blood count and BM aspiration with examination of 
well prepared films by Leishman and peroxidase stains, flow-
cytometric immunophenotypic analysis of peripheral blood 
(PB) and/or BM aspirates, conventional cytogenetic analysis OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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by G-banding (Giemsa staining), and K-RAS   mutation 
detection using real-time polymerase chain reaction (PCR). 
Lab investigations were carried out at the Clinical Pathology 
Department of Zagazig University Hospital.
cytogenetic analysis
cultivation and harvesting
All reagents were supplied by GIBCO-BRL (Invitrogen Carls-
bad, CA). BM was cultured (two tubes for each patient) on 
RPMI-1640 (Sigma-Aldrich, St Louis, MO) to which fetal calf 
serum, L-glutamine, and penicillin/streptomycin were added; 
the tubes were then incubated at 37°C in a CO2 incubator 
for 24 and 48 hours. Colcemid was added to arrest mitosis 
followed by hypotonic treatment of the cell pellets and sub-
sequent fixation with methanol–acetic acid solution.12
slide preparation and banding
Fixed cells were then dropped onto a frosted, alcohol-cleaned 
slide. Aging of slides for 24 hours in an incubator at 37°C 
was done for proper banding. At least five slides were pre-
pared for each patient and evaluated under the phase contrast 
microscope for metaphases. Banding with trypsin solution 
and counterstaining with Giemsa was performed. The slides 
were examined microscopically using an oil emersion lens. 
At least 20 metaphases were subjected to analysis; we used 
an Imstar image analyzer for karyotyping (Paris, France).
DnA extraction and rAs mutations detection
All molecular analyses were conducted in a blinded fashion 
on DNA extracted from cryopreserved cells taken at the 
time of diagnosis. Seventy-four patients were submitted for 
  analysis; however, three (4%) were deemed ineligible because 
of defective DNA samples. Screening for RAS mutations was 
performed using real-time PCR in 71 patients.
DnA extraction
PB mononuclear cells were isolated on a Ficoll gradient. DNA 
was isolated using standard procedure and extracted promptly 
using DNA extraction and purification kit (High Pure PCR 
Template Preparation Kit; Roche Diagnostics, Mannheim, 
Germany) according to manufacturer’s instructions. The eluted 
purified DNA was stored at −80°C until used.
real-time assay
The method was carried out on the LightCycler instrument 
(Roche Diagnostics), comprising of amplification of a 171 bp 
fragment of the K-RAS gene using specific primers, together 
with hybridization probes labeled with LightCycler Red 640.
The detection depends on the fact that the amplification of 
the wild type K-RAS codons 12/13 DNA is suppressed by a 
competitor so that its melting peak at 64.7°C was not detect-
able, whereas mutants of K-RAS codons 12/13 DNA show 
melting peaks of 61.0°C in channel 640/530.
Pcr protocol
PCR was performed in glass capillary tubes using 1 µL 
of genomic DNA and LightMix Kit K-RAS codons 12/13 
(Roche Diagnostics) with final volume of 20 µL. The PCR 
program started with incubation at 95°C for 10 minutes, 
followed by 45 cycles of PCR amplification. Each cycle 
consists of three segments with three different temperatures: 
denaturation at 95°C for 10 seconds, annealing at 58°C for 
10 seconds, and extension at 72°C for 25 seconds. The 
temperature was then increased at a rate of 0.1°C/second 
up to 85°C with continuous fluorescence monitoring. The 
software provided with the equipment gives the temperature 
of melting; the mutation detection was achieved by melting 
curve analysis. In samples with wild-type K-RAS, no melting 
curve will be displayed.
response to therapy
CR was defined as the presence of morphologically normal 
BM in patients with at least 1.5 × 109/L granulocytes and 
100 × 109/L platelets in the blood. Relapse was defined 
as .5% leukemic blasts in a BM aspirate or new extramed-
ullary leukemia. Overall survival (OS) was measured from 
the protocol on-study date until the date of death regard-
less of cause, censoring for those alive at last follow-up. 
Disease-free survival (DFS) was estimated from the time 
of first CR to relapse or death in CR. Patients who were 
still alive and disease free were censored at the date of last 
follow up.
statistical methods
Statistical analysis of data was performed with SPSS computer 
program (version 16.0;SPSS Inc., Chicago, IL). Data are 
presented as median and ranges. Student’s t-test, Mann–
hitney U-test, chi-square, and Fisher’s exact test were used 
for comparison between groups. Kaplan–Meier method was 
used to estimate survival, and the differences between groups 
were analyzed using logrank test. P , 0.05 was considered 
significant.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Results
Eighty-nine patients participated in this study. Fifteen were 
excluded after induction chemotherapy (four died and 11 
failed to attain remission). Another three patients were 
excluded because of defective DNA samples. K-RAS muta-
tion detection and statistical analyses were carried out for 
the remaining 71 patients, who comprised 42 males and 29 
females with male/female ratio 1.4:1; their ages ranged from 
21 to 59 years with a median of 37 years.
Mutations in K-RAS were detected in leukemic cells 
from 23 patients (32%), with the remaining 48 patients 
(68%) having wtRAS alleles. Table 1 shows comparison of 
clinical and hematological features of AML patients with 
and without K-RAS mutations. No statistically significant 
differences were found for age, hepatomegaly, splenomegaly 
or lymphadenopathy, hemoglobin level, platelet count, or 
total lymphocyte count. The median of BM and PB blasts 
percent was significantly higher in mutRAS compared to 
wtRAS patients (P , 0.001 and P = 0.025, respectively).
Thirty-nine patients were assigned to HDAC therapy 
(13 mutant and 26 wild RAS), while 32 patients were 
assigned to receive LDAC (10 mutant and 22 wild), with 
nonstatistical difference in the percentage of patients with 
respect to the mutational status in each group (P = 0.852).
Table 1 comparison of clinical and hematological features of 
AML patients with and without rAs mutations
Character mutRAS  
n = 23 (32%)
wtRAS  
n = 48 (68%)
P-value
Age (years)  
  Median (range)
 
36 (21–56)
 
39 (22–59)
 
0.474
Organomegalya 
hepatomegaly 
splenomegaly 
Lymphadenopathy
 
2 (40%) 
7 (41%) 
6 (29%)
 
3 (60%) 
10 (59%) 
15 (71%)
 
0.656b 
0.375 
0.656
hb (g/dL) 
  Median (range)
 
7.9 (4.1–10.6)
 
8.2 (5.2–11.3)
 
0.361
Platelet (109/L) 
  Median (range)
 
48 (25–88)
 
4 (30–122)
 
0.453
TLc (109/L) 
  Median (range)
 
57.5 (11–213)
 
73.0 (21–193)
 
0.491
BM blasts (%) 
  Median (range)
 
55 (38–78)
 
84 (30–98)
 
,0.001*
PB blasts (%)  
  Median (range)
 
30 (10–65)
45 (10–95) 0.025*
consolidation ttt 
  hDAc (39) 
  LDAc (32)
13 (33%) 
10 (31%)
26 (67%)  
22 (69%)
0.852
Notes: *Significant;  aThe patient may have more than one site of organomegaly; 
bFisher’s exact test.
Abbreviations:  AML,  acute  myeloid  leukemia;  hb,  hemoglobin;  TLc,  total 
lymphocyte  count;  BM,  bone  marrow;  PB,  peripheral  blood;  hDAc,  high-dose 
cytarabine; LDAc, low-dose cytarabine.
Table 2 relationship between FAB subtypes and rAs mutation
M0 
n = 4
M1 
n = 8
M2 
n = 18
M4 
n = 24
M5 
n = 17
P-valuea
Mutated K-rAs 
(n = 23)
0 
(0%)
1 
(12%)
3 
(17%)
14 
(58%)
5 
(29%) 0.015
Wild K-rAs 
(n = 48)
4 
(100%)
7 
(88%)
15 
(83%)
10 
(42%)
12 
(71%)
Notes: Data presented as number (%); aFisher’s exact test.
Abbreviation: FAB, French–American–British.
Table 3 relationship between cytogenetic groups and rAs mutation
Normal karyotype 
n = 44
t (8;21) 
n = 13
Inv (16) 
n = 14
P-valuea
Mutated K-rAs 
(n = 23)
10 
(23%)
3 
(23%)
10 
(71%)
0.003
Wild K-rAs 
(n = 48)
34 
(77%)
10 
(77%)
4 
(29%)
Notes: Data presented as number (%); aFisher’s exact test.
K-RAS mutation demonstrated significant heterogeneity 
among FAB subgroups, being more common in M4 (P = 0.015) 
(Table 2). Also K-RAS mutation varied between karyotypic sub-
types, with evident overrepresentation in inv(16) (p13; q22) com-
pared to othercytogenetic groups. Inv(16) was significantly higher 
in mutRAS cases than in wtRAS cases (P = 0.003) (Table 3).
The patients were followed up for a median of 43 months 
(range 11–57 months). There was no significant difference 
in OS between mutRAS and wtRAS (P = 0.326) (Figure 1). 
Within the mutRAS group, cumulative OS at four years in 
patients treated with HDAC was significantly higher than 
those treated with LDAC (P = 0.001) (Figure 2). This was 
not the case in the wtRAS group (P = 0.285) (Figure 3).
There was no significant difference in DFS between 
mutRAS and wtRAS groups (P = 0.923). When both the RAS 
status and consolidation therapy were taken into account, 
mutRAS patients treated with HDAC had a statistically higher 
cumulative survival than mutRAS patients treated with LDAC 
(P = 0.001) (Table 4).
Patients with wtRAS also benefited from HDAC, but to 
a lesser extent. Among patients with wtRAS, those treated 
with HDAC showed higher cumulative and median DFS than 
patients treated with LDAC (P = 0.031).
Discussion
Mutations in the RAS proto-oncogenes have been implicated in 
the genesis of AML and have been described in approximately 
25% of cases.13 This frequency makes aberrations in RAS the 
most common molecular abnormality in this heterogeneous 
disease. Despite the prevalence of RAS mutations, the clinical 
significance of such molecular aberrations in AML is unclear. OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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proliferation and enhanced maturation and differentiation of 
leukemic cells;16 this is a possible explanation.
We demonstrated an association between K-RAS muta-
tion frequency and M4 subtype of AML. This finding may 
provide indirect evidence in implicating K-RAS mutation as 
an important functional pathologic event in selected cases 
of AML. Selection and expansion of K-RAS mutant clones 
may provide a differentiative stimulus toward the monocytic 
lineage, given that K-RAS mutation was overrepresented in 
FAB subtypes M4 and M5. In vitro data also suggest that 
mutant RAS promotes a myeloid maturation defect, with 
relative sparing of the monocyte/macrophage lineage.17
Evaluation of K-RAS mutation in association with 
  karyotype revealed a high frequency of inv(16) in patients 
with K-RAS mutation compared to patients with wtRAS. This 
is consistent with the finding of Valk et al who proposed that 
signal transduction pathway mutations are common with RAS 
mutation.18 Our sample size for inv(16) was small, and inde-
pendent confirmation of the high K-RAS mutation frequency 
is required from larger cohorts. However, this finding is in 
harmony with the higher prevalence of K-RAS mutation in 
M4 as inv(16) is most frequently encountered in this group.
Earlier studies of the prognostic significance of mutations 
of K-RAS in AML showed contradictory results. Some stud-
ies reported that patients with RAS mutations had improved 
OS,16,19 whereas others found that these patients had worse 
complete remission rate and OS.20 In most of these studies, 
the type of postremission treatment was not taken in account 
in the analysis of clinical outcome.21,22
However, when we considered the K-RAS status and 
consolidation therapy, statistical analysis revealed that the 
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Figure  1  Overall  survival  of  AML  patients  according  to  rAs  mutation  status 
(mutrAs and wtrAs).
Abbreviation: AML, acute myeloid leukemia.
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Figure  2  Overall  survival  of  AML  patients  with  mutant  rAs  according  to 
consolidation therapy (hDAc and LDAc).
Abbreviations: hDAc, high-dose cytarabine; LDAc, low-dose cytarabine; AML, 
acute myeloid leukemia. 
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Figure 3 Overall survival of AML patients with wild rAs according to consolidation 
therapy (hDAc and LDAc).
Abbreviations: hDAc, high-dose cytarabine; LDAc, low-dose cytarabine; AML, 
acute myeloid leukemia.
To assess the impact of K-RAS mutations on this disease, we 
sought to analyze a relatively uniform cohort of de novo AML 
patients who were diagnosed in a standard fashion and treated 
with different dose intensity chemotherapeutic regimens.
The frequency of K-RAS mutation in our small cohort 
of AML patients was comparable with that reported in the 
literature (12%–44%).5,14 The largest study described data 
from 232 patients with (28%) RAS mutations.15
Unexpected findings emerged from our study. A   significant 
association was gleaned between the presence of a K-RAS 
mutation and a lower fraction of blasts in the BM. Currently, 
we have no biologic explanation for this result. However, 
a strong RAS activation may be associated with reduced OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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impact of K-RAS mutations on OS and DFS in our AML 
patients depends on the type of postremission chemotherapy. 
Kaplan–Meier analysis of our data revealed that the prob-
ability of OS at four years for mutRAS and wtRAS groups 
is comparable, whereas the estimated four years OS among 
patients with mutRAS assigned to HDAC was significantly 
higher than in those subjected to LDAC, an observation 
which was not found in patients with wtRAS. Although 
therapy with HDAC resulted in a higher DFS both in patients 
with and without RAS mutations, its benefit was much more 
pronounced in patients with mutRAS. In vitro data showed 
that mutations in K-RAS render tumor cell lines derived 
from AML, nonsmall-cell lung cancer, and colon carcinoma 
more sensitive to certain cytotoxic drugs, such as ara-C or 
topoisomerase II inhibitors.23
Koo et al have demonstrated that cells harboring an 
activated RAS oncogene fail to arrest in the S-phase of 
the cell cycle in response to cytarabine treatment and that 
this results in their apoptotic death. In contrast, tumor 
cells with wtRAS genes undergo marked S-phase growth 
arrest on exposure to ara-C that is reversible once the drug 
is removed. The authors concluded that the presence of 
a RAS mutation may change cellular response to ara-C 
from cytostatic to cytotoxic, most likely because of altered 
cellular checkpoint functions in response to ara-C.24 Other 
studies provide experimental evidence that mutated RAS 
not only induces proliferation, apoptosis, senescence, or 
differentiation (depending on the cellular context in which 
it is expressed), but it may also induce a DNA damage 
checkpoint response.25–27 These results provide biologic 
plausibility to our clinical observations.
Conclusion
This study evaluating AML patients with mutant K-RAS sug-
gests that HDAC consolidation chemotherapy is critical for 
treating such patients. It is also possible that alternative treat-
ment approaches that use more intensive induction therapy will 
be equally effective in treating this mutant subtype of AML. 
If our findings are confirmed, testing for K-RAS mutations 
could become crucial, in addition to abnormal cytogenetic 
AML detection, for risk adapted stratification to HDAC pos-
tremission treatment in adults with de novo AML. As new 
parameters with powerful prognostic significance are rapidly 
evolving, considering all variables in one comprehensive 
model is likely to provide more exact quantitative estimations 
of the prognosis. These prognostic distinctions are likely to 
provide the elementary foundations for treatment choice in 
the near future.
Table 4 Overall survival at four years and disease-free survival at three years of the AML patients and their relationship to rAs 
mutational state and consolidation therapy
No Cumulative survival Median ± SE 95% CI P-value
Overall survival
Whole group 71 67.5% 57.0 ± 2.2 52.7–61.3
rAs gene
Mutant rAs 23 62.2% 54.0 ± 6.3 41.6–66.4
Wild rAs 48 52.1% 57.0 ± 2.9 51.3–62.7 0.326
Mutant rAs
hDAc 13 90.9% * *
LDAc 10 21.4% 35.0 ± 15.9 3.9–66.1 0.001
Wild rAs
hDAc 26 57.3% * *
LDAc 22 61.4% * * 0.258
Disease-free survival
Whole group 71 50.7% 37.0 ± 2.8 31.5–42.5
rAs gene
Mutant rAs 23 47.8% 33.0 ± 7.2 18.9–47.1
Wild rAs 48 52.1% 37.0 ± 3.0 31.2–42.8 0.923
Mutant rAs
hDAc 13 69.2% * *
LDAc 10 20.0% 14.0 ± 2.4 9.4–18.7 0.001
Wild rAs
hDAc 26 73.1% 47.0 ± 2.6 41.8–52.2
LDAc 22 27.3% 26.0 ± 3.5 19.1–32.9 0.031
Notes: *no median survival because more than half of the patients are alive.
Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; SE, standard error; HDAC, high-dose cytarabine; LDAC, low-dose cytarabine.OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open access 
journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
121
K-rAs mutations in adult acute myeloid leukemia patients
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Chan IT, Kato JL, Williams LR, et al. Conditional expression of onco-
genic K-ras from its endogenous promoter induces a myeloproliferative 
disease. J Clin Invest. 2004;113(4):528–538.
  2.  Downward J. Targeting RAS signaling pathways in cancer therapy. Nat 
Rev Cancer. 2003;3(1):11–22.
  3.  Haferlach T. Molecular genetic pathways as therapeutic targets in 
acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 
2008:400–411.
  4.  Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated 
by the Ras/Raf, MEK, and ERK pathway from cytokine receptors to 
transcription factors: potential targeting for therapeutic intervention. 
Leukemia. 2003;17(7):1263–1293.
  5.  Illmer T, Thiede C, Fredersdorf A, et al. Activation of the RAS pathway 
for a chemosensitive phenotype of acute myelogenous leukemia blasts. 
Clin Cancer Res. 2005;11(9):3217–3224.
  6.  Barletta E, Gorini G, Vineis P, et al. RAS gene mutations in patients 
with acute myeloid leukemia and exposure to chemical agents. Car-
cinogenesis. 2004;25(5):749–755.
  7.  Benanti JA, Galloway DA. The normal response to RAS: senescence 
or transformation? Cell Cycle. 2004;3(6):715–717.
  8.  Milella M, Komblau SM, Estrov Z, et al. Therapeutic targeting of the 
MEK/MAPK signal transduction module in acute myeloid leukemia. 
J Clin Invest. 2001;108(6):851–859.
  9.  Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras 
oncogene and the effect of chemotherapy in advanced adenocarcinoma 
of the lung: a prospective study. J Clin Oncol. 1997;15(1):285–291.
  10.  Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 
and N-RAS gene mutations in acute myeloid leukemia. Blood. 
1999;93(9):3074–3080.
  11.  Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and 
TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 
2001;97(11):3589–3595.
  12.  Seabright M. A rapid banding technique for human chromosomes. 
Lancet. 1971;2(7731):971–972.
  13.  Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and 
prognostic significance of mutations in codon 13 of the N-ras gene in 
acute myeloid leukemia. Leukemia. 1994;8(10):1682–1687.
  14.  Tyner JW, Erichson H, Deininger MW, et al. High-throughput sequenc-
ing screen reveals novel transforming RAS mutations in myeloid 
leukemia patients. Blood. 2009;113(8):1749–1755.
  15.  Ritter M, Kim TD, Lisske P, Thiede C, Schaich M, Neubauer A. Prog-
nostic significance of N-RAS and K-RAS mutations in 232 patients with 
acute myeloid leukemia. Haematologica. 2004;89(11):1397–1399.
  16.  Neubauer A, Dodge RK, George SL, et al. Prognostic importance of 
mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. 
Blood. 1994;83(6):1603–1611.
  17.  Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid 
leukemia is associated with distinct cytogenetic subgroups but does 
not influence outcome in patients younger than 60 years. Blood. 
2005;106(6):2113–2119.
  18.  Valk PJ, Bowen DT, Frew ME, Goodeve AC, Lowenberg B, Reilly JT. 
Second hit mutations in the RTK/RAS signaling pathway in acute 
myeloid leukemia with inv(16). Haematologica. 2004;89(1):106.
  19.  Schaich M, Ritter M, Illmer T, et al. Mutations in ras proto-oncogenes 
are associated with lower mdr1 gene expression in adult acute myeloid 
leukemia. Br J Haematol. 2001;112(2):300–307.
  20.  Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations 
of RTK/RAS signal transduction pathway in pediatric acute myeloid 
leukemia. Blood. 2003;102(4):1474–1479.
  21.  Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic 
Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative 
disorder. Proc Natl Acad Sci U S A. 2004;101(2):597–602.
  22.  Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implica-
tions of NRAS mutations in AML: a study of 2502 patients. Blood. 
2006;107(10):3847–3853.
  23.  Koo HM, Monks A, Mikheev A, et al. Enhanced sensitivity to 
1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors 
in tumor cell lines harboring activated ras oncogenes. Cancer Res. 
1996;56(22):5211–5216.
  24.  Koo HM, McWilliams MJ, Alvord WG, Vande Woude GF. RAS 
oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. 
Cancer Res. 1999;59(24):6057–6062.
  25.  Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senes-
cence is a DNA damage response triggered by DNA hyper-replication. 
Nature. 2006;444(7119):638–642.
  26.  Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA. 
Oncogenic RAS induces accelerated transition through G2/M and pro-
motes defects in the G2 DNA damage and mitotic spindle checkpoints. 
J Biol Chem. 2006:281(7):3800–3809.
  27.  Fikaris AJ, Lewis AE, Abulaiti A, Tsygankova OM, Meinkoth JL. Ras 
triggers ataxia-telangiectasia-mutated and Rad-3-related activation 
and apoptosis through sustained mitogenic signaling. J Biol Chem. 
2006;281(46):34759–34767.